title: [Lichen sclerosus--clinical and therapeutic aspects].
abstract: Lichen sclerosus (LS) is a lymphocyte-mediated inflammatory dermatosis with a characteristic location (85-98%) in the anogenital region. The authors point out the main features in the epidemiology and clinical presentation of the disease and the possible approach to neoplastic development. Expanded differential diagnosis of LS sparked not only dermatologists but also gynecologists, urologists and GPs. Points are the chronic course of the disease and resistance to therapy. Discuss the results of the treatment of LS with less potent topical corticosteroids, calcineurin inhibitors, phototherapy and photodynamic therapy, surgery.
authors.forename: G
authors.initials: G
authors.lastname: Manolova
authors.forename: G
authors.initials: G
authors.lastname: Pehlivanov
authors.forename: I
authors.initials: I
authors.lastname: Bakardzhiev
authors.forename: M
authors.initials: M
authors.lastname: Saleva
authors.forename: I
authors.initials: I
authors.lastname: Yungareva
authors.forename: P
authors.initials: P
authors.lastname: Lozanova
authors.forename: K
authors.initials: K
authors.lastname: Prisadashka
authors.forename: Zh
authors.initials: Zh
authors.lastname: Karagiozova
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000453:epidemiology / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D010789:Phototherapy / Q000379:methods; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology
chemical_list: D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors